CurrentBlue Cross Blue Shield - IowaPolicy 05.04.34

Lupkynis (voclosporin) for lupus nephritis — Coverage Criteria

Covers medical necessity, prior authorization, and coverage criteria for Lupkynis (voclosporin) when used to treat adult patients with active lupus nephritis, including documentation and dosing/quantity limits for members of Wellmark / Blue Cross Blue Shield - Iowa.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyLupkynis (voclosporin) for lupus nephritis — Coverage Criteria

Policy CodePolicy 05.04.34

Change TypeNo material change

Effective DateMay 17, 2023

Next Review DateApr 1, 2026

Key ActionObtain prior authorization with required medical records showing autoantibody or biopsy confirmation and evidence the member is on MMF plus corticosteroids.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsapproval duration

≥45eGFR cutoff

180/30dqty limit (capsules)

23.7 mg BIDFDA dosing

Coverage Criteria for Lupkynis (voclosporin)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Approval Criteria

Lupkynis (voclosporin) may be considered medically necessary when ALL of the following are met:

Initial therapy criteria: Prior to initiating therapy, the member is positive for autoantibodies relevant to SLE (e.g., ANA, anti-dsDNA, anti-Sm, antiphospholipid antibodies, complement proteins) OR lupus nephritis confirmed on kidney biopsy.

Initial therapy criteria: Member has clinically active lupus renal disease and is receiving background therapy with mycophenolate mofetil (MMF) with corticosteroids.

Initial therapy criteria: Medication is being prescribed by, or in consultation with, a nephrologist or rheumatologist.

Initial therapy criteria: Member must have an eGFR ≥ 45 mL/min per 1.73 m2.≥ 45 mL/min/1.73 m2

Continuation of Therapy

Continued treatment may be considered medically necessary when:

Continuation criteria: Member achieves or maintains a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of lupus nephritis.

Approval duration: 12 months.

Restriction: Lupkynis (voclosporin) must not be used in combination with cyclophosphamide. Use of Lupkynis with cyclophosphamide is not recommended and coverage will not be provided for members receiving both agents.

If the member does not meet the policy's specified approval criteria for Lupkynis, the use of Lupkynis is considered not medically necessary and will not be covered.

Provider Actions and Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior authorization required — submission of medical records per documentation requirements and initial criteria must be met before approval.

Prior authorization required before initiating Lupkynis (voclosporin).
Initial clinical criteria and documentation (see documentation callout) must be met for approval.
Approval duration: 12 months.

Prior Authorization

Background Therapy Requirement

Background therapy requirement — Member must be receiving background therapy with mycophenolate mofetil (MMF) and corticosteroids prior to or concomitantly with Lupkynis.

Member must be on MMF plus corticosteroids as background therapy.
Treatment should be managed by or in consultation with a nephrologist or rheumatologist.

Documentation Required

Required Documentation

Required documentation — Initial requests require medical records documenting presence of SLE-relevant autoantibodies or kidney biopsy supporting diagnosis; continuation requests require records showing disease stability or improvement.

Initial requests: chart notes and lab reports documenting positive SLE autoantibodies (e.g., ANA, anti-dsDNA, anti‑Sm, antiphospholipid antibodies, complement proteins) OR kidney biopsy confirming lupus nephritis.
Continuation requests: chart notes and lab reports demonstrating disease stability or improvement.
Prescriber: documentation that medication is prescribed by or in consultation with a nephrologist or rheumatologist, and baseline eGFR ≥ 45 mL/min/1.73 m2.

Denial Risk

Triggers for Denial

Triggers for denial — Deny if member does not meet clinical criteria, required documentation is not provided, or if Lupkynis is used concurrently with cyclophosphamide.

Use with cyclophosphamide — not covered; combination therapy with cyclophosphamide is exclusionary.
Missing documentation — deny if initial or continuation medical records required are not submitted.
Clinical criteria not met — deny if member lacks positive SLE autoantibodies or kidney biopsy confirmation, is not on required background MMF + corticosteroids, eGFR < 45 mL/min/1.73 m2, or prescriber is not a nephrologist/rheumatologist or consulted with one.
Not meeting duration/indication — deny if indication is not lupus nephritis or member fails to meet all initial approval criteria.

Background

Lupkynis (voclosporin) is an oral calcineurin inhibitor indicated in combination with background immunosuppressive therapy for the treatment of adult patients with active lupus nephritis. The product labeling and this policy align on that indication and on limitations of use: use in combination with cyclophosphamide has not been established and is not recommended. This policy requires members to meet specified clinical criteria (including autoantibody or biopsy confirmation, background therapy with mycophenolate mofetil plus corticosteroids, and baseline renal function of eGFR ≥ 45 mL/min/1.73 m2) for approval; requests that do not meet those criteria are considered not medically necessary. Approval, when granted, is for 12 months.